68480-12-6Relevant articles and documents
Synthesis of quaternary carbon stereocenters by copper-catalyzed asymmetric allylic substitution of allyl phosphates with arylboronates
Takeda, Momotaro,Takatsu, Keishi,Shintani, Ryo,Hayashi, Tamio
, p. 2354 - 2367 (2014/04/17)
A copper-catalyzed asymmetric allylic substitution of γ,γ- disubstituted allyl phosphates with arylboronates has been developed for the construction of quaternary stereocenters. High regio- and enantioselectivities have been achieved by employing a hydroxy-bearing chiral N-heterocyclic carbene ligand, and both E and Z substrates provide the same enantiomer as the major product. The mechanistic aspect of this catalysis has also been investigated to find that a 1:1 copper/ligand complex is most likely responsible for the present asymmetric catalysis, and the reaction proceeds with almost perfect 1,3-anti stereochemistry with respect to the allylic electrophile.
1-Imidazolyl(alkyl)-substituted di- and tetrahydroquinolines and analogues: Syntheses and evaluation of dual inhibitors of thromboxane A2 synthase and aromatase
Jacobs, Christoph,Frotscher, Martin,Dannhardt, Gerd,Hartmann, Rolf W.
, p. 1841 - 1851 (2007/10/03)
A series of 1-imidazolyl(alkyl)-substituted quinoline, isoquinoline, naphthalene, benzo[b]furan, and benzo[b]thiophene derivatives was synthesized as dual inhibitors of thromboxane A2 synthase (P450 TxA2) and aromatase (P450 arom). Dual inhibition of these enzymes could be a novel strategy for the treatment of mammary tumors and the prophylaxis of metastases. The most potent dual inhibitors, 5-(2-imidazol-1-ylethyl)-7,8-dihydroquinoline (31) (P450 TxA2:IC50 = 0.29/μM; P450 arom: IC50 = 0.50/μM) and its 5,6- saturated analogue 30 (P450 TxA2:IC50 = 0.68/μM; P450 arom: IC50 = 0.38/μM), showed a stronger inhibition of both target enzymes than the reference compounds (dazoxiben: IC50 = 1.1/μM; aminoglutethimide: IC50 = 18.5/μM). For the determination of the in vivo activity, the influence of selected compounds on serum TxB2 concentration was examined in rats. Compound 30 (8.5 mg/kg body weight) led to a reduction of the TxB2 serum level of 78%, 71%, and 51% after 3, 5, and 8 h, respectively (dazoxiben: 60%, 34%, and 36%). Selectivity was studied toward some enzymes of the steroidogenic and eicosanoid pathways. P450 17 was inhibited by selected compounds only at high concentrations. Compound 30 inhibited P450 scc by 13% (25/μM). Compound 31 did not affect cyclooxygenase and lipoxygenase.
N-[ω-(tetralin-1-yl)alkyl] derivatives of 3,3-dimethylpiperidine are highly potent and selective σ1 or σ2 ligands
Berardi, Francesco,Santoro, Sergio,Perrone, Roberto,Tortorella, Vincenzo,Govoni, Stefano,Lucchi, Laura
, p. 3940 - 3947 (2007/10/03)
Several 3,3-dimethyl-N-[ω-(tetrahydronaphthalen-1-yl)alkyl]piperidine derivatives and some related compounds were prepared. Their affinities and σ-subtype selectivities were investigated by radioligand binding assays, labeling σ1 receptors with [3H]-SKF 10047 and σ2 receptors with [3H]- DTG. Many tested compounds bound σ1 and/or σ2 receptors with nanomolar or subnanomolar IC50 values. Compound (+)-22, (+)-3,3-dimethyl-1-[3-(5- methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)-n-propyl]piperidine, was the most potent (IC50 = 0.089 nM) and selective σ1 ligand (1340-fold), showing a 10-fold enantioselectivity. Compounds 29 (3,3-dimethyl-1-[4 (6-methoxy- 1,2,3,4-tetrahydronaphthalen-1-yl)-n-butyl]piperidine) and 31 (3,3-dimethyl- 1-[5-(1,2,3,4-tetrahydronaphthalen-1-yl)-n-pentyl]piperidine) were highly potent (IC50 = 0.016 nM and IC50 = 0.008 nM, respectively) and highly selective σ2 ligands (more than 100 000-fold).